Acorda Therapeutics Inc., of Ardsley, N.Y., said it will discontinue development of Plumiaz (diazepam) nasal spray, in development for treating seizure clusters in epileptics, after data from an ongoing trial did not demonstrate the bioequivalence to Diastat rectal gel needed for filing a new drug application under the 505(b)(2) pathway.